Tehran (IP) - Spokesman for the National Task Force for Fighting Coronavirus said that the COV-Iran Barekat vaccine, by having the needed antibodies, was 97 percent effective to treat the novel virus.

Iran Press/Iran News: In an interview with Iran Press on the effectiveness of the COV-Iran Barekat vaccine to treat the British mutated COVID-19, Alireza Raisi announced that the second phase of the vaccination would start in March, and it was estimated to reach industrial production in mid-April.

"In May, if all the approved steps go well, Iran will have about one and a half million doses of production capacity per month," he said.

Responding to Iran Press on the sidelines of the "Infection Control for Emergency Response Personnel" (ICERP) inauguration held at the Health Ministry, Raisi announced the full readiness of industrial equipment to produce domestic vaccines, saying Iran would produce 10-15 million monthly doses in March.

One of the effective measures taken in vaccine production was the sampling of those infected with COVID-19 nationwide. The samples were amplified and tested twice in laboratories to test the effectiveness of the COV-Iran Barekat vaccine which fortunately has worked well.

The inauguration of "Infection Control for Emergency Response Personnel" (ICERP) was held at the Health Ministry to cover different parts of the country, including Bam, Alborz, Bojnord, Shiraz, and Isfahan.

The ceremony was attended by Iran's Health Minister, Saeid Namaki, President Rouhani's Adviser for Supervision and Strategic Affairs and Head of Plan and Budget Organization, Mohammad Baqer Nobakht, Regional Director for the Eastern Mediterranean at the World Health Organization (WHO), Ahmed Al-Mandhari, the WHO Representative in the Islamic Republic of Iran, Christoph Hamelmann, and some other officials.


Read more:

COVIran reaches to human trial before 7 other candidates

Iran succeeded in producing COVID-19 vaccine though being sanctioned: Official